Cell and gene therapies. ([2019])

• Record Type: Book
• Further Information: Note: Miguel-Angel Perales, Syed A. Abutalib, Catherine Bollard, editors.
• Editors: Perales, Miguel-Angel; Abutalib, Syed A; Bollard, Catherine
• Contents: Intro; Contents; 1: Historical Perspective and Current Focus; 2: Most Recent Clinical Advances in CAR T Cell and Gene Therapy 2017/2018; 2.1 Introduction; 2.2 Relapsed/Refractory B-Lineage Acute Lymphoblastic Leukemia; 2.2.1 Children and Young Adults: CAR T Cells Show Promising Results; 2.2.2 Children and Young Adults: Tisagenlecleucel (CTL019) and Its US FDA Approval (2017); 2.2.3 Adults with Relapsed/Refractory B-ALL: Phase I Trial from Memorial Sloan Kettering Cancer Center (MSKCC); 2.3 Non-Hodgkin B-Cell Lymphomas 2.3.1 Phase I, ZUMA-1 Study (Locke et al. 2017a): Primary Results of Axicabtagene Ciloleucel (KTE-C19) with a Focus on Refractory Diffuse Large B-Cell Lymphoma (DLBCL)2.3.2 Additional Results of ZUMA-1 Study (Locke et al. 2017b) and US FDA Approval (2017) of Axicabtagene Ciloleucel (KTE-C19); 2.3.3 Phase II Results of ZUMA-1 Study (Neelapu et al. 2017): Axicabtagene Ciloleucel in DLBCL, PMBCL, and Transformed FL; 2.3.4 Tisagenlecleucel (CTL019) in Relapsed/Refractory DLBCL and Follicular Lymphoma: Results from University of Pennsylvania (UPenn) (Schuster et al. 2017a) 2.3.5 US FDA Approval (2018) of Tisagenlecleucel (CTL019) for Adults with Relapsed/Refractory Large B-Cell Lymphoma: Results of JULIET Study (Schuster et al. 2017b, c)2.3.6 Long Duration of CR in DLBCL After Anti-CD19 CAR T-Cell Therapy: Data from the NCI (Kochenderfer et al. 2017); 2.4 Chronic Lymphocytic Leukemia; 2.4.1 CLL and Anti-CD19 CAR T Cells Following Ibrutinib Failure; 2.5 Multiple Myeloma; 2.5.1 Results of Anti-BCMA CAR T Cells: Data from NCI (Ali et al. 2016; Brudno et al. 2017); 2.5.2 Anti-BCMA CAR T Cells: Data Presented at ASH® 2017 by UPenn (Cohen et al. 2017) 2.5.3 CRB-401: A Multicenter Trial Phase I Dose Escalation Trial of bb21212.5.4 Data from China with Unique Antigen-Binding Domain: Late Breaking Abstract at ASCO® 2017; 2.6 Classic Hodgkin and Anaplastic Large-Cell Lymphomas; 2.6.1 CD30-Directed CAR T Cell: Phase I Study in Patients with Relapsed/Refractory Classic Hodgkin Lymphoma (cHL) and Anaplastic Large-Cell Lymphoma (ALCL); 2.6.2 CD30-Directed CAR T Cell: Another Phase I Study in Patients with Relapsed/Refractory cHL and ALCL; 2.7 Considerations for Tisagenlecleucel Dosing Rationale
• Publisher Details: Cham, Switzerland : Springer
• Publication Date: 2019
• Extent: 1 online resource (vi, 288 pages)
• Subjects: 615.8/9; Cellular therapy; Gene therapy; Cellular therapy; Gene therapy; Cell- and Tissue-Based Therapy; Genetic Therapy; Electronic books
• Languages: English
• ISBNs: 9783319543680; 3319543687
• Related ISBNs: 9783319543673
• Notes: Note: Description based upon print version of record.
• Access Rights: Legal Deposit; Only available on premises controlled by the deposit library and to one user at any one time; The Legal Deposit Libraries (Non-Print Works) Regulations (UK).
• Access Usage: Restricted: Printing from this resource is governed by The Legal Deposit Libraries (Non-Print Works) Regulations (UK) and UK copyright law currently in force.